Our vision is to be recognised as a global leader in providing innovative treatments that transform life for people living with rare diseases.
We aim to grow within Haematology, increasing penetration of our market-leading extended half-life factor replacement treatments and realising the potential of new assets.
We see significant potential for growth in our Immunology portfolio, and will work to extract maximum value.
We continue to expand geographically, building up our operations in North America and the EMENAR region, and establishing in Asia.
And we continue to strengthen our R&D pipeline with late-stage assets that we see address unmet medical need and have great potential market value.